Yue Hsin Lin
Founder at LIN BIOSCIENCE, INC.
Net worth: 77 M $ as of 2024-04-29
Yue Hsin Lin active positions
Companies | Position | Start | End |
---|---|---|---|
LIN BIOSCIENCE, INC. | Founder | 2016-05-11 | - |
Chairman | 2016-05-11 | - | |
Investor Relations Contact | 2016-05-11 | - | |
Chief Executive Officer | 2016-05-31 | 2022-03-31 | |
BELITE BIO, INC | Chief Executive Officer | 2018-03-26 | - |
Chairman | 2018-03-26 | - | |
Founder | 2018-03-26 | - | |
Belite Bio LLC
Belite Bio LLC Pharmaceuticals: MajorHealth Technology Part of Lin BioScience, Inc., Belite Bio LLC is a clinical stage biopharmaceutical drug development company based in San Diego, CA. Tinlarebant has been granted fast track designation and rare pediatric disease designation in the US and orphan drug designation in the EU for the treatment of STGD1. Belite Bio is focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, type 1, or STGD1. The company's lead candidate, Tinlarebant, is a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA). Belite Bio is currently conducting a two-year phase 2 study and enrolling patients in a two-year phase 3 study (Dragon) of Tinlarebant in adolescent STGD1 subjects and plans to begin enrolling patients in a two-year phase 3 study (Phoenix) of Tinlarebant in GA in mid-2023. The company was founded in 2016 by Cheng Chi Wang. | President | 2021-09-30 | - |
RBP4 Pty Ltd. | Director/Board Member | 2018-07-31 | - |
Chief Executive Officer | 2021-03-31 | - | |
Belite Bio Holdings Corp. | Chief Executive Officer | 2017-11-30 | - |
Chairman | 2016-05-31 | - | |
President | 2021-09-30 | - | |
Belite Bio (HK) Ltd. | Director/Board Member | 2021-05-31 | - |
Career history of Yue Hsin Lin
Former positions of Yue Hsin Lin
Companies | Position | Start | End |
---|---|---|---|
CVie Therapeutics Ltd.
CVie Therapeutics Ltd. BiotechnologyHealth Technology Founded in 2013, CVie Therapeutics Ltd. is a subsidiary of Windtree Therapeutics, Inc. The company is based in Taipei, Taiwan. The Taiwanese company develops and researches drugs. | Chief Operating Officer | 2013-12-31 | 2015-12-31 |
President | 2013-12-31 | 2015-12-31 | |
OBI PHARMA, INC. | Chief Tech/Sci/R&D Officer | 2009-12-31 | 2013-12-31 |
ASLAN PHARMACEUTICALS LIMITED | Chief Tech/Sci/R&D Officer | 2013-12-31 | - |
Training of Yue Hsin Lin
The University of Sydney | Doctorate Degree |
The Trustees of Columbia University in The City of New York | Masters Business Admin |
University of Hong Kong | Masters Business Admin |
University of Pennsylvania | Undergraduate Degree |
London Business School | Masters Business Admin |
Statistics
International
United States | 6 |
Taiwan | 4 |
Australia | 3 |
Operational
Chief Executive Officer | 4 |
Chairman | 3 |
Masters Business Admin | 3 |
Sectoral
Health Technology | 7 |
Consumer Services | 6 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 4 |
---|---|
LIN BIOSCIENCE, INC. | Health Technology |
BELITE BIO, INC | Health Technology |
ASLAN PHARMACEUTICALS LIMITED | Health Technology |
OBI PHARMA, INC. | Health Technology |
Private companies | 5 |
---|---|
Belite Bio LLC
Belite Bio LLC Pharmaceuticals: MajorHealth Technology Part of Lin BioScience, Inc., Belite Bio LLC is a clinical stage biopharmaceutical drug development company based in San Diego, CA. Tinlarebant has been granted fast track designation and rare pediatric disease designation in the US and orphan drug designation in the EU for the treatment of STGD1. Belite Bio is focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, type 1, or STGD1. The company's lead candidate, Tinlarebant, is a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA). Belite Bio is currently conducting a two-year phase 2 study and enrolling patients in a two-year phase 3 study (Dragon) of Tinlarebant in adolescent STGD1 subjects and plans to begin enrolling patients in a two-year phase 3 study (Phoenix) of Tinlarebant in GA in mid-2023. The company was founded in 2016 by Cheng Chi Wang. | Health Technology |
RBP4 Pty Ltd. | |
Belite Bio Holdings Corp. | |
CVie Therapeutics Ltd.
CVie Therapeutics Ltd. BiotechnologyHealth Technology Founded in 2013, CVie Therapeutics Ltd. is a subsidiary of Windtree Therapeutics, Inc. The company is based in Taipei, Taiwan. The Taiwanese company develops and researches drugs. | Health Technology |
Belite Bio (HK) Ltd. |
- Stock Market
- Insiders
- Yue Hsin Lin
- Experience